MedPage Today on MSN
ADCs continue to make first-line inroads in triple-negative breast cancer
ADCs have moved from the salvage setting into first-line treatment ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Aditya Bardia, MD, ...
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
Antibody-drug conjugates (ADCs), a class of potent biopharmaceutical agents that target specific cancer cells, are associated with relevant antitumor activity across breast cancer subtypes. Medscape ...
Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...
Pharmaceutical Technology on MSN
Biocytogen and Whitehawk partner to develop ADCs
The collaboration leverages Biocytogen’s antibody capabilities and Whitehawk’s ADC expertise to identify BsADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results